Iovance Biotherapeutics
Iovance is focused on the commercialization of autologous tumor Infiltrating lymphocyte (TIL) Therapies that amplify the body’s own immune response in order to eradicate solid tumors. Iovance is conducting multiple Phase 2 trials with its investigational therapies and has reported clinically meaningful responses in disease areas or populations with unmet medical need, most notably in patients who have progressed on available therapy including immune checkpoint inhibitors. Accruing phase 2 clinical trials in metastatic melanoma, SCCHN, NSCLC, cervical cancer and multiple solid tumors.